NCT04018664View on ClinicalTrials.gov

Oral Abuse Potential Study of Nalbuphine

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

December 3, 2018

Study Completion Date

June 2, 2020

Conditions

NalbuphineOpioid Abuse

Interventions

DRUG

Nalbuphine HCl solution

nalbuphine solution administered at various strengths

DRUG

Placebo solution

Placebo

Trial Locations (1)

M5V 2T3

001, Toronto

Sponsors

Lead Sponsor

Trevi Therapeutics

Collaborators (1)

All Listed Sponsors

collaborator

Syneos Health

OTHER

lead

Trevi Therapeutics

INDUSTRY